Biogen shares, which had been halted, were up 5% at $285.19.
Initial patient access will be limited by a number of factors including reimbursement decisions from Medicare, the US government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi. The US Centers for Medicare & Medicaid Services said on Friday that current coverage restrictions for drugs approved under the accelerated pathway could be reconsidered based on its ongoing review of available information.
Lecanemab is intended for patients with mild cognitive impairment or early Alzheimer’s dementia, a population that doctors believe represents a small segment of the estimated 6 million Americans currently living with the memory-robbing illness.
I'm really grateful for all the efforts you have render to me with my little investment of R5000 and with joy over me after withdrawing R60,000 with your help Lisa_berry77 thank you for everything you have done for me and my family Lisa_berry77
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: ITNewsAfrica - 🏆 27. / 59 더 많은 것을 읽으십시오 »